阿托伐他汀治疗血管性认知功能障碍的疗效观察被引量：1

Efficacy of atorvastatin in treatment of vascular cognitive impairment

导出

摘要目的探讨阿托伐他汀对血管性认知功能障碍的临床疗效。方法将160例血管性认知功能障碍患者随机分为治疗组(80例)和对照组(80例),均接受常规药物治疗,治疗组同时加用阿托伐他汀。结果两组MMSE积分治疗后均有提高(P<0.01),治疗组总有效率明显高于对照组(P<0.05)。结论阿托伐他汀对治疗血管性认知功能障碍是安全有效的。 Objective To study clinical efficacy of atorvastatin on vascular cognitive impairment.Methods Totally 160 patients with vascular cognitive impairment were randomly divided into treatment group（80 cases） and control group（80 cases）,were receiving conventional drug therapy,the treatment group were added atorvastatin.Results MMSE points after treatment were improved（P0.01）,the efficiency of the treatment group was significantly higher（P0.05）.Conclusions Atorvastatin for the treatment of vascular cognitive impairment is safe and effective.

作者郭爱香

机构地区安阳钢铁集团公司职工总医院神经内科

出处《医药论坛杂志》 2011年第3期91-92,共2页 Journal of Medical Forum

关键词血管性认知功能障碍阿托伐他汀疗效 Vascular cognitive impairment Atorvastatin Effect

分类号 R749.92 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献9

1Hachinski VC. Bowler JV. Vascular dementia [ J ]. Neu- rology, 1993,43 ( 10 ) :2159-2160.
2Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke Canadian stroke network vascular cognitive impairment harmoniza- tion standards [ J ]. Stroke,2006,37 (9) :2220-2241.
3Desmond DW. The neurosychology of vascular cognitive impairment is there a specific cognitive deficit [ J ]. J Neurol Sci ,2004,226( 1 - 2) :3-7.
4龚耀先,江这威,邓君林,等.修订韦氏记忆量表手册[M].2版.长沙:湖南医科大学出版社,1989:1-8.
5Erkiniuntti T, Gauthier S. The concept of vascular cogni- tive impairment [ J ]. Front Neurol Neurosci, 2009,24 : 79-85.
6Bowler JV. Modern Concept of Vasculer Cognitive Im-parement[ J]. Br Med Bu11,2007,83:291-305.
7顾萍,蒋卫民.他汀类药物防治阿尔茨海默病的作用机制[J].中国老年学杂志,2005,25(2):221-222. 被引量：11
8李珺,吴家幂,储照虎,沈衡升.他汀类药物神经保护作用的研究进展[J].国际脑血管病杂志,2006,14(9):696-699. 被引量：20
9Cramer C, Haan MN, Galea S, et al. Use of statins and incidence of dem entia and cognitive impairment with-out dementia in a cohort study [ J ]. Neurology, 2008,71 (5) :344-350.

二级参考文献50

1Notkola l,Sulkava R,Pekkanen J,et al . A serum total cholesterol level,age,and sex in prediction of Alzheimer's disease [J]. Neuroepidemiology, 1998 ; 17 : 14-20.
2Green RC,Mcagny SE,Jayak.nmr P,et al . Statin use is associated with reduced risk of Alzheimerfs disease [J]. Neurology,2002 ;58 :A81.
3Bemick CB,Katz B,BaPP SB,et al. Cholesterol,statins,and cognitive function in the elderly [J]. Cardiovascular Heath Study,2003 ;60:A132.
4Naidu A,Xu Q,Catalano R,et al. Secretion of apolipoprotein E by statins [J]. Brain Res,2002 ;958 (1) : 100-11.
5Gibson Wood W,Eckert GP,Igbavboa V,et al. Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimers disease [J]. Biochim Biophys Acta,2003;1610(2) :281-90.
6Kojro E, Gimpl G, lammich S, et al . Low cholesterol stimulates thenonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10[J]. Proc Natl Acad Sci USA,2001 ;98:5815-20.
7Sidera C,Liu C,Auaten B. Cholesterol levels influence eelluar processing and targeting of beta-secretase[J]. Neurobiol Aging, 2002;23 (1S):S140-1.
8Beyreuther K,Hartman T. Cholesterol-dependent Abem generation [J}.Neurobiol Aging,2002;23(lS) :S146-7.
9Fassbender K, Simmm M,Bergamann C,et al. Simvastain strongly reduces levels of Alzheimers disease beta-amyloid peptides Abeta42 and Abeta40 in vitro and vivo [J]. Proc Natl Acad Sei USA,2001;98.5856-61.
10Luetijohann D,Sueiek M,BetUteh ,et al . Effects of statlns on cerebral cholesterol metabolism and secretion of Alzheimer's amyloid peptide[J]. Neurobiol Aging,2002 ;23 (IS) :S134.